IMV to Host a Webcast to Highlight its Immune-Educating DPX Platform

0
64

IMV to Host a Webcast to Highlight its Immune-Educating DPX Platform

The event will feature Michael Kalos, Ph.D., member of IMV’s Board of Directors and internationally recognized expert in T cell therapy and immunotherapy

Live webinar on Thursday, February 24th 8amET, registration details below

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today announced that it is hosting a Research and Development Day” via webcast on Thursday, February 24, 2022, at 8:00 am Eastern Time to highlight the differentiating features of its patented DPX delivery platform.

IMV’s DPX technology is a delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. This versatile, immune-educating technology is being developed for application in a variety of therapeutic areas (e.g., oncology, infectious disease) where the generation of a target-specific immune response is expected to mitigate disease.

The webcast will feature a presentation by Michael Kalos, Ph.D., Key Opinion Leader (KOL) and member of IMV’s board of directors, who will discuss the potential of IMV’s DPX delivery platform in addressing unmet medical needs in the current and future oncology landscape.

The IMV team will describe the DPX delivery platform technology and its differentiated immune-educating capabilities, highlighting key advantages demonstrated in both clinical and preclinical studies including its favorable safety profile. IMV management will also provide an update on the Company’s clinical programs and discuss key expected milestones in 2022. A live question and answer session will follow.

Michael Kalos, Ph.D. is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience and expertise in cell therapy, oncology vaccines, and immune-oncology. Dr. Kalos has held executive and R&D leadership positions in biopharma at Arsenal Bio, Janssen, and Eli Lilly. Prior to his career in the biopharmaceutical sector, Dr. Kalos spent 10 years in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs.

The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the clinical cell therapy program at Penn, including the development of the CTL019 program, which was licensed to Novartis and led to Kymriah, the first approved CART cell therapy product.

Dr. Kalos obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center. He has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy.

He also has over 26 issued patents in the fields of cell therapy, immunotherapy, and vaccines. Dr. Kalos now actively serves in an advisory capacity for a number of biopharmaceutical companies as well as international immunotherapy consortia and organizations.

https://www.imvaccine.com/

#IMV #Immune-Educating #DPX Platform #webcamhost

LEAVE A REPLY

Please enter your comment!
Please enter your name here